Group 1 - The core point of the article is that the company, Zhixiang Jintai, has received acceptance for its new drug application for GR2001 injection, which is currently in the review queue, but did not apply for priority review during the listing application process [2][3] - The GR2001 injection is recognized as a breakthrough therapy, indicating its potential significance in treatment [2] - The new drug application was officially accepted in May 2025, suggesting a timeline for potential market entry [2]

Core Viewpoint - The company has confirmed the receipt of a $20 million upfront payment related to the licensing and commercialization agreement for the GR1803 injection with Cullinan, and will recognize this revenue according to accounting policies [1] Group 1 - The company has received the $20 million upfront payment as part of the agreement with Cullinan [1] - The licensing and commercialization agreement for GR1803 injection has been signed and is in effect [1] - The company advises investors to refer to its announcements and periodic reports for detailed information [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2024/10/16 回购方案实施期限 2024 年 10 月 15 日~2025 年 10 月 14 日 预计回购金额 2,000万元~4,000万元 回购价格上限 39.83元/股 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 实际回购股数 796,100股 实际回购股数占总股本比例 0.2171% 实际回购金额 20,297,339.45元 实际回购价格区间 22.89元/股~29.43元/股 一、 回购审批情况和回购方案内容 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）于 2024 年 10 月 15 日召开第一届董事会第十六次会议，审议通过了《关于以集中竞价交易方式回购 股份的方案》，同意公司以集中竞价交易方式回购公司 A 股股份，回购的 A 股股 份拟用于员工持股计划或股权激励，回购资金金额不低于人民币 2,000 万元，不超 过人民币 4,000 万元，回购价格不 ...

证券日报网讯7月30日晚间，智翔金泰发布公告称，2025年7月30日，公司完成回购，已实际回购公司股 份796，100股，占公司总股本的0.2171%。 ...

每经AI快讯，智翔金泰（SH 688443，收盘价：33.41元）7月30日晚间发布公告称，2025年7月30日，公 司完成回购，已实际回购公司股份约80万股，占公司总股本的0.2171%，回购最高价格29.43元/股，回 购最低价格22.89元/股，回购均价约25.5元/股，使用资金总额约2030万元。 每经头条（nbdtoutiao）——装个"AI脑"售价飙十倍！马斯克已下场，阿里、美团等大厂前高管正涌 入，这个万亿级赛道火了 （记者 王晓波） 2024年1至12月份，智翔金泰的营业收入构成为：医药制造业占比99.92%，其他业务占比0.08%。 截至发稿，智翔金泰市值为123亿元。 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-030 二、 回购实施情况 （一）2024 年 11 月 19 日，公司首次实施回购股份，并于 2024 年 11 月 20 日 披露了首次回购股份情况，详见公司披露于上海证券交易所（www.sse.com.cn）及 指定信息披露媒体上的《关于首次回购股份的公告》（公告编号 2024-039）。 重庆智翔金泰生物制药股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/16 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 10 月 10 | 15 | 日~2025 | 年 | 14 日 | 月 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | 回购价格上限 | 39.83元/股 | | | | | | | 回购用途 | □ ...

格隆汇7月30日丨智翔金泰(688443.SH)公布，2025年7月30日，公司完成回购，已实际回购公司股份 79.61万股，占公司总股本的0.2171%，回购最高价格29.43元/股，回购最低价格22.89元/股，回购均价约 25.50元/股，使用资金总额2029.73万元（不含佣金、过户费等交易费用）。 ...

Group 1: Company Announcements - Zhixiang Jintai received approval for clinical trials of its drug, Sileweimi Monoclonal Antibody Injection, for passive immunity in children and adolescents exposed to suspected rabies virus [1] - Liyuan Technology's actual controller, Shen Wanzhong, received a criminal judgment for violating information disclosure laws, resulting in a one-year prison sentence with a one-and-a-half-year probation and a fine of 3.3 million yuan [1] - Shijia Photon reported a net profit of 217 million yuan for the first half of 2025, a year-on-year increase of 1712% [2] - Xinghua New Materials expects a net profit of 75 million to 85 million yuan for the first half of 2025, representing a year-on-year growth of 12.37% to 27.36% [3] - Greenland Holdings achieved a contract sales amount of 21.752 billion yuan in the second quarter, a year-on-year increase of 16.93% [4] Group 2: Shareholder Actions - Bluefeng Biochemical announced that a shareholder plans to reduce its stake by up to 2.61% [5] - Jiahe Meikang's shareholder intends to reduce its stake by up to 3% [5] - Lakaala reported that Lenovo Holdings reduced its stake by 535,960 shares, representing 0.68% of the total share capital [12] - Anji Food's controlling shareholder plans to reduce its stake by up to 2% [16] - Tongding Interconnect's shareholder plans to reduce its stake by up to 2.08% [20] Group 3: Strategic Partnerships and Investments - Yitian Intelligent signed distribution agreements with SMEG and Simico for a three-year period [6] - Daoshi Technology entered into a strategic cooperation agreement with Nengsida and Chipason to collaborate on materials for humanoid robot components [22]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，公司在研产品斯乐韦米单抗注射液2岁至18岁以下儿童和青少年疑似狂 犬病病毒暴露后的被动免疫适应症的临床试验申请获得批准。现将相关情况公告如下： 一、药品基本信息 药品名称：斯乐韦米单抗注射液 申请事项：境内生产药品注册临床试验 申请人：重庆智翔金泰生物制药股份有限公司 受理号：CXSL2500414 适应症：2岁至18岁以下儿童和青少年疑似狂犬病病毒暴露后的被动免疫 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，斯乐韦米单抗注射液临床试验申 请符合药品注册的有关要求，同意本品开展2岁至18岁以下儿童和青少年疑似狂犬病病毒暴露后的被动 免疫适应症的临床试验。 重庆智翔金泰生物制药股份有限公司董事会 2025年7月30日 二、药品其他相关情况 斯乐韦米单抗注射液是一款由公司自主研发的重组全人源抗狂犬病 ...

Macro News - The International Monetary Fund (IMF) has significantly raised China's economic growth forecast for this year by 0.8 percentage points to 4.8%, reflecting stronger-than-expected economic activity in the first half of the year and lower actual tariff rates compared to previous predictions [4] - In the first half of the year, state-owned enterprises in China reported total operating revenue of 4,074.96 billion yuan, a year-on-year decrease of 0.2%. Their total profit amounted to 218.25 billion yuan, down 3.1% year-on-year, and tax payments were 300.26 billion yuan, a decline of 0.8% [4] Industry News - Hong Kong's "Stablecoin Regulation" will come into effect on August 1, with the Hong Kong Monetary Authority releasing five regulatory documents for licensed stablecoin issuers [7] - The China Photovoltaic Industry Association issued a statement refuting claims made by some media regarding "anti-involution" in the photovoltaic industry, particularly concerning polysilicon, stating that the reports were severely inconsistent with actual conditions [7] Company News - WuXi AppTec announced an adjustment to its share repurchase price ceiling to no more than 114.15 yuan per share [11] - The PCB industry is experiencing a significant improvement in market conditions compared to the same period last year, especially for high-end products, with strong demand and rising prices [9] - Changchun High-tech announced that its innovative drug, Amlodipine Besylate Oral Solution, has received approval from the FDA for market launch in the United States [12]